6 Takeaways From Novartis FCPA Case

Law360, New York (April 7, 2016, 10:21 AM EDT) -- Gary F. Giampetruzzi

S. Joy Dowdle

Jena A. Sold In yet another resolution in life sciences, the U.S. Securities and Exchange Commission announced its settlement with Novartis AG, resolving allegations that two China-based Novartis subsidiaries violated the Foreign Corrupt Practices Act by providing gifts, cash payments and entertainment to health care professionals (HCPs) and engaging in "pay-to-prescribe schemes to increase sales" — conduct Novartis neither admits nor denies in the March 23, 2016, cease-and-desist order.[1] Under the resolution, available here, Novartis will pay $25 million and engage in a two-year self-monitorship to resolve the alleged improper activity and related books and records...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!